Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) is a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, at the level of C3, the central protein in the complement cascade.